EPISODE · Aug 7, 2026 · 32 MIN
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
from The BioCentury Show · host BioCentury
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biotech industry, and why he is optimistic about the future of biotech.View full story: https://www.biocentury.com/article/660408#Biotech #DrugPricing #BiopharmaPolicy #ChinaBiotech #Innovation00:00 - Introduction03:24 - Biotech Under Threat10:38 - CEO Compensation15:39 - Competing with China22:08 - U.S. Policy Prescriptions30:00 - Looking Ahead
Embed this episode
What this episode covers
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up to its ideals. In an interview with BioCentury Washington Editor Steve Usdin, Levin discussed why he believes industry leaders should speak out, and why many remain silent, about critical issues. He described concerns about the strength of the pillars that support the U.S. biot...
NOW PLAYING
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.